Purpose of review: To discuss novel drug formulations being developed for the medical treatment of acromegaly and to highlight recent data from studies reporting more effective therapeutic strategies using existing drugs.
Recent findings: Despite advances in the management of acromegaly a significant number of patients remain uncontrolled. Primary medical treatment is being increasingly considered, but use of somatostatin analogues, the current mainstay of medical therapy, achieves control in only around 60% of patients, whilst 10-20% may be controlled with dopamine agonists. Consequently, improvements in drug efficacy and convenience are needed. Newer longer-acting somatostatin analogues are in development and combination regimes with the growth hormone receptor antagonist, pegvisomant, given at more cost-effective weekly doses show promising results. Somatostatin analogue-resistant tumours may respond to ligands with higher affinities to other receptors, such as pasireotide (SOM 230). Further, the combined dopamine/somatostatin receptor analogue BIM-23A760 has increased affinity to somatostatin receptors 2 and 5 and to the dopamine 2 receptor, and phase 2 clinical studies are underway.
Summary: These novel drugs, formulations and treatment regimes should potentially add to the armamentarium of treatment options for patients with acromegaly.